BioCatalystWatch
PTGXWorkspace / PTGX / OverviewCompany library
Protagonist Therapeutics, Inc logo

Protagonist Therapeutics, Inc

Protagonist Therapeutics, Inc (PTGX)

Website

Price
Market cap
Next catalystHistorical PN-458 Phase 1 initiation forecast: Q4 2026; formulation unspecifiedPN-458 — planned oral-formulation Phase 1 · Trial initiationCompany source ↗
Cash

Chart & Events

Candle interval

Core Clinical

PN-477o

GLP-1R × GIPR × GCGR

PreINDP2P3FilingApproved
Upcoming / outlook

  • Timing and evidence

PN-881

IL-17AA × IL-17AF × IL-17FF

PreINDP1P3FilingApproved
Upcoming / outlook

PN-8047

PreINDP2P3FilingApproved
Upcoming / outlook

  • Timing and evidence

PN-458

GLP-1R × GIPR

PreINDP2P3FilingApproved
Upcoming / outlook

PN-477sc

GLP-1R × GIPR × GCGR

PreINDP2P3FilingApproved
Upcoming / outlook

PN-881

IL-17AA × IL-17AF × IL-17FF

PreINDP1P2P3FilingApproved

Technology Summary

Scientific context

Detailed technology interpretation

Technology advantages

Representative pipeline applications

Disease and market context

Detailed science focus

Background, answer, next evidence

Clinical

Upcoming clinical milestones

PN-881

IL-17AA × IL-17AF × IL-17FF

PreINDP1P3FilingApproved
Upcoming / outlook

PN-8047

PreINDP2P3FilingApproved
Upcoming / outlook

  • Timing and evidence

PN-477o

GLP-1R × GIPR × GCGR

PreINDP2P3FilingApproved
Upcoming / outlook

  • Timing and evidence

PN-477sc

GLP-1R × GIPR × GCGR

PreINDP2P3FilingApproved
Upcoming / outlook

PN-458

GLP-1R × GIPR

PreINDP2P3FilingApproved
Upcoming / outlook

PN-881

IL-17AA × IL-17AF × IL-17FF

PreINDP1P2P3FilingApproved

Other pipelines

PN-881

IL-17AA × IL-17AF × IL-17FF

PreINDP1P2P3FilingApproved
Upcoming / outlook

PN-477

GLP-1R × GIPR × GCGR

IL-4Rα

Partner / License out

IL-23R

PreINDP1P2P3FilingApproved

IL-23R

PreINDP1P2P3FilingApproved

IL-23R

PreINDP1P2P3FilingApproved

IL-23R

IL-23R

PreINDP1P2P3FilingApproved

PreINDP1P2P3FilingApproved

PreINDP1P2P3FilingApproved

History / paused

PreINDP1P2P3FilingApproved

IL-23R

PreINDP1P2P3FilingApproved

α4β7 integrin

PreINDP1P2P3FilingApproved
PTG-100

α4β7 integrin

PreINDP1P2P3FilingApproved

IL-23R

PreINDP1P2P3FilingApproved

Financial position

Net operating cash flow

Source and basis

Company funding outlook

Upcoming milestones

Financial history

Amounts and sources
PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing



PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing




PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

Annual trends

Reported item

Reported shares and borrowings

Ownership and institutions

Status

Market Reaction / Supply Context

Market Structure

PTGX PR & News

PR & News

PTGX SEC archive